Adicet Bio, Inc.

Adicet Bio discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Lead product candidate ADI-001 targets CD20 in Phase I trial for autoimmune diseases and lymphoma. Company also developing ADI-270 for renal cell carcinoma and other solid tumors/hematological malignancies. Founded in 2014, based in Boston, MA.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

0.8 USD

Potential

-100%

Strengths

Price to book ratio (0.33) is lower than the sector mean (24.44).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.4

Adicet Bio, Inc.

Overview

Strengths

Weaknesses

Key Financial Data